TY - JOUR
T1 - Primary treatment and prognostic factors of small cell neuroendocrine carcinoma of the uterine cervix
T2 - A Taiwanese Gynecologic Oncology Group study
AU - Wang, Kung Liahng
AU - Chang, Ting Chang
AU - Jung, Shih Ming
AU - Chen, Chi Hau
AU - Cheng, Ya Min
AU - Wu, Hua Hsi
AU - Liou, Wen Shiung
AU - Hsu, Shih Tien
AU - Ou, Yu Che
AU - Yeh, Lian Shung
AU - Lai, Hung Cheng
AU - Huang, Chia Yen
AU - Chen, Tze Chien
AU - Chang, Chee Jen
AU - Lai, Chyong Huey
N1 - Funding Information:
This work was supported by grants from the National Science Council-Taiwan (NSC 98-2314-B-182-047-MY3) and the Department of Health, Taiwan (DOH99-TD-B-111-005 and DOH100-TD-C-111-005).
PY - 2012/7
Y1 - 2012/7
N2 - Background: Our aims were to investigate the treatment and clinicopathological variables in relation to prognosis in small cell neuroendocrine cervical carcinoma (SCNECC). Patients and methods: Clinical data of SCNECC patients with International Federation of Gynaecology and Obstetrics (FIGO) stages I-IV treated between 1987 and 2009 at member hospitals of the Taiwanese Gynecologic Oncology Group (TGOG) were retrospectively reviewed. Results: Of the 179 eligible patients, 104 were of FIGO stage I, 19 stage IIA, 23 stage IIB, 9 stage III, and 24 stage IV. The median failure-free survival (FFS) was 16.0 months, and the median cancer-specific survival (CSS) was 24.8 months. In multivariate analysis, FIGO stage and lymph node metastasis were selected as independent variables in stages I-IV. In stages IIB-IVB, primary treatment containing etoposide and platinum for at least 5 cycles (EP5+) (n = 16) was associated with significantly better 5-year FFS (42.9% versus 11.8%, p = 0.041) and CSS (45.6% versus 17.1%, p = 0.035) compared to other treatments (n = 40). Furthermore, concurrent chemoradiation with EP5+ (CCRT-EP5+) was associated with even better 5-year FFS (62.5% versus 13.1%, p = 0.025) and CSS (75.0% versus 16.9%, p = 0.016). Conclusions: FIGO stage and lymph node metastasis are significant prognostic factors in SCNECC. In stages IIB-IVB, CCRT-EP5+ might be the treatment of choice, which could be also true for earlier stages. Despite limitations of a retrospective study spanning a long time period and heterogeneous managements, the results provide an important basis for designing future prospective studies.
AB - Background: Our aims were to investigate the treatment and clinicopathological variables in relation to prognosis in small cell neuroendocrine cervical carcinoma (SCNECC). Patients and methods: Clinical data of SCNECC patients with International Federation of Gynaecology and Obstetrics (FIGO) stages I-IV treated between 1987 and 2009 at member hospitals of the Taiwanese Gynecologic Oncology Group (TGOG) were retrospectively reviewed. Results: Of the 179 eligible patients, 104 were of FIGO stage I, 19 stage IIA, 23 stage IIB, 9 stage III, and 24 stage IV. The median failure-free survival (FFS) was 16.0 months, and the median cancer-specific survival (CSS) was 24.8 months. In multivariate analysis, FIGO stage and lymph node metastasis were selected as independent variables in stages I-IV. In stages IIB-IVB, primary treatment containing etoposide and platinum for at least 5 cycles (EP5+) (n = 16) was associated with significantly better 5-year FFS (42.9% versus 11.8%, p = 0.041) and CSS (45.6% versus 17.1%, p = 0.035) compared to other treatments (n = 40). Furthermore, concurrent chemoradiation with EP5+ (CCRT-EP5+) was associated with even better 5-year FFS (62.5% versus 13.1%, p = 0.025) and CSS (75.0% versus 16.9%, p = 0.016). Conclusions: FIGO stage and lymph node metastasis are significant prognostic factors in SCNECC. In stages IIB-IVB, CCRT-EP5+ might be the treatment of choice, which could be also true for earlier stages. Despite limitations of a retrospective study spanning a long time period and heterogeneous managements, the results provide an important basis for designing future prospective studies.
UR - http://www.scopus.com/inward/record.url?scp=84862819949&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862819949&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2011.12.014
DO - 10.1016/j.ejca.2011.12.014
M3 - Article
C2 - 22244826
AN - SCOPUS:84862819949
SN - 0959-8049
VL - 48
SP - 1484
EP - 1494
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 10
ER -